drugset / Trial / NCT06834789
A Study to Assess the Adverse Events of Intramuscular Injections of AGN-151586 and OnabotulinumtoxinA in Adult Participants for the Change of Glabellar Lines (GL)
RandomizedParallel-groupDouble-blindTreatment
Summary
The objective of this Phase 1 study is to assess the safety and efficacy of single treatment of AGN-151586 and of OnabotulinumtoxinA in the glabellar complex of participants with moderate to severe glabellar lines (GL).
Timeline
- Start
- 2025-02-18
- Primary completion
- 2025-11-03
- Completion
- 2025-11-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | AGN-151586 | Unknown | — | Intramuscular |
| Subject | Botulinum toxin type A | Protein / enzyme biologic | — | Intramuscular |
Indications
No indication recorded.